---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-016410"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:20:38.820209+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M

## Summary
- Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.
- GAAP net loss $133.7M ($2.32/sh) includes $112.9M non-cash impairment on Avedro intangible.
- Non-GAAP net loss improved to $16.4M ($0.28/sh) from $22.2M ($0.40) in Q4 2024.
- U.S. Glaucoma sales record $86.4M, +53% YoY; strong growth from iDose TR.
- Ended Q4 with $282.6M cash, no debt; 2026 revenue guidance reaffirmed at $600-620M.

## SEC filing metadata
- accession: 0001104659-26-016410
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000110465926016410/0001104659-26-016410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000110465926016410/gkos-20260217x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-016410
- JSON: https://secwatch.observer/filing/0001104659-26-016410.json
- Plain text: https://secwatch.observer/filing/0001104659-26-016410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.